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ABSTRACT
Introduction: New-generation drug-eluting
stents (NG-DES) are superior to early generation
DES (EG-DES) in the majority of lesion and
patient subsets, but comparative data in
patients with severely calcified coronary lesions
are lacking. This study aims to compare clinical
outcomes of EG-DES and NG-DES in patients
undergoing rotational atherectomy (RA) in cal-
cified lesions.
Methods: Data of 268 patients (288 lesions)
treated with EG-DES and 213 patients (225
lesions) receiving NG-DES after RA were retro-
spectively analyzed from a single-center reg-
istry. All major adverse cardiac events (MACE)
were assessed at 2 years.
Results: Compared to the EG-DES group,
patients with NG-DES more commonly had
diabetes mellitus (31.9% vs. 40.9%; p = 0.04),
left main lesions (7.6% vs. 17.3%; p\0.001)
and chronic total occlusions (3.5% vs. 8.5%;
p = 0.016), and had a higher total stent length
(30.5, IQR 20–40 mm, vs. 38, IQR 22–53 mm,
p\0.001). The Kaplan–Meier estimated rate of
cardiovascular events at 2 years showed a lower
incidence of death (13.5% vs. 8.2%, log-rank
p = 0.13; adjusted HR after Cox regression
analysis 0.49; 95% CI 0.26–0.92; p = 0.03) and a
lower MACE rate (31.1% vs. 21.1%, log-rank
p = 0.04; adjusted HR 0.65; 95% CI 0.42–0.98;
p = 0.04) in the NG-DES group.
Conclusions: Although RA is performed in
more complex patients and lesions in the
NG-DES era, use of NG-DES is associated with
lower rates of death and MACE at 2 years as
compared to EG-DES.
Keywords: Calcified coronary stenosis;
Drug-eluting stents; Rotational atherectomy
INTRODUCTION
Rotational atherectomy (RA) is a safe and
effective atheroablative technique for complex
heavily calcified coronary lesions [1, 2]. How-
ever, RA as a stand-alone therapy is associated
with high rates of restenosis [3, 4], and although
results improved with the emergence of bare
metal stents (BMS), the elevated rates of target
lesion revascularization (TLR) remained an
important limitation [5]. With the introduction
of drug-eluting stents (DES) and the growing
number of coronary interventions in severely
calcified morphologies, the interest in RA
resurged [6–9].
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The randomized ROTAXUS (Rotational
Atherectomy Prior to Taxus Stent Treatment for
Complex Native Coronary Artery Disease) trial
showed a superior strategy success of routine
lesion preparation using RA compared to bal-
loon angioplasty in the setting of complex cal-
cified coronary lesions treated with early
generation paclitaxel-eluting stents, but it failed
to demonstrate improved long-term clinical
outcomes with such an approach [10, 11].
New-generation drug-eluting stents
(NG-DES) are characterized by thinner stent
strut platforms, polymers with improved bio-
compatibility and limus-based antiprolifera-
tive agents, thereby providing an improved
safety and efficacy profile as compared to BMS
as well as first-generation drug-eluting devices
in the majority of lesion and patient subsets
[12, 13]. Currently, there is a paucity of data
supporting the benefit of NG-DES in patients
with severely calcified coronary lesions [14].
In particular, it is not known whether delicate
NG-DES have enough mechanical stability to
make them applicable in this challenging type
of lesions. The current study compares clinical
outcomes of EG- and NG- DES in an all-com-
ers population of patients with severely calci-
fied lesions treated with RA prior to stent
implantation.
METHODS
This is a retrospective analysis of prospectively
collected data in patients who underwent RA
followed by DES implantation for the treatment
of calcified coronary lesions at a single tertiary
center (Heart Center, Segeberger Kliniken, Bad
Segeberg, Germany) between November 2002
and June 2015. Patients treated with BMS, with
a combination of BMS and DES or early plus
new-generation DES as well as bioresorbable
vascular scaffolds (BVS) were excluded from this
analysis.
For the current study, two groups of patients
depending on the type of stent implanted after
RA were compared: the first group included
patients receiving only EG-DES including the
sirolimus-eluting CypherTM stent (Cordis, Miami
Lakes, FL, USA) and the paclitaxel-eluting Taxus
Liberte´TM stent (Boston Scientific, Boston, MA,
USA). The NG-DES group consisted of patients
receiving only NG-DES, including the cobalt-
chromium everolimus-eluting XienceTM stent
(Abbott Vascular, Santa Clara, CA, USA), the
platinum-chromium everolimus-eluting Pro-
musTM stent (Boston Scientific, Natick, MA, USA)
as well as the sirolimus-eluting OrsiroTM stent
(Biotronik, Bu¨lach, Switzerland).
Written informed consent was obtained
from all patients for analysis of their anon-
ymized data, and data collection was
approved by the local ethics committee. All
procedures followed were in accordance with
the ethical standards of the responsible com-
mittee on human experimentation and with
the Helsinki Declaration of 1964, as revised in
2013.
In addition to demographic and clinical
characteristics of the study population, data
collection included angiographic and procedu-
ral details as well as early in-hospital outcome
and long-term follow-up. Clinical follow-up was
obtained either by on-site clinical visit or
scripted telephone interview with the patients
or their general practitioners.
Procedural Details
For all cases, RA was performed using the
CE-marked Rotablator device (Boston Scientific
Scimed Inc., Maple Grove, MN, USA). The burr
size was selected aiming at a burr/vessel ratio of
0.5 (max. 0.7 if needed). Rotational speed ran-
ged between 140,000 and 180,000 rotations per
minute (rpm). To prevent slow-flow, a contin-
uous intracoronary infusion of unfractioned
heparin (UFH), nitroglycerine and verapamil
was used during RA. Prior to RA, patients were
treated with 325–500 mg aspirin intravenously
and an oral loading dose of a P2Y12 inhibitor
(Clopidogrel, Prasugrel or Ticagrelor). In addi-
tion, patients were administrated a periproce-
dural anticoagulation with either UFH
intra-arterially or bivalirudin. The use of glyco-
protein IIb/IIIa inhibitors was at the operator’s
discretion. Technical details of RA at our insti-
tution have been reported in previous publica-
tions [8].
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Definitions, Follow-Up, and Endpoints
RA was defined as elective in the absence of any
previous attempt to cross the lesion with a bal-
loon or a stent. Angiographic success was
defined as a final residual stenosis \30% and
grade 3 thrombolysis in myocardial infarction
(TIMI) flow. During hospitalization, occurrence
of any adverse event and any additional coro-
nary intervention were registered. Periprocedu-
ral myocardial infarction following PCI was
defined as CK-MB elevation[3 times the upper
range limit of normal at 48 h after the proce-
dure. Major adverse cardiac events (MACE) were
defined as all cause death, spontaneous
myocardial infarction (MI) and target vessel
revascularization (TVR). Death was classified as
either cardiac or non-cardiac, and death of
unknown cause was adjudicated as cardiac
death. Stent thrombosis and myocardial infarc-
tion (MI) were defined according to the Aca-
demic Research Consortium [15]. TVR was
defined as any repeat PCI or surgical bypass of
the target vessel. Finally, target lesion revascu-
larization was defined as any repeat revascular-
ization either with PCI or coronary artery
bypass graft (CABG) for restenosis or other
complication inside the stent implanted during
the index procedure or within 5 mm proximal
or distal to the stent.
Statistical Methods
Continuous variables are expressed as
mean ± standard deviation or median and
interquartile range, as appropriate. Categorical
variables are expressed as numbers and per-
centages. Group comparisons were performed
using Student’s t test or Wilcoxon rank-sum test
for continuous variables or Chi-square and
Fisher’s exact tests for categorical variables.
Kaplan–Meier plots of cumulative incidence of
MACE, death, MI, TVR, and TLR were con-
structed from the index procedure until 2-year
follow-up, and log-rank tests were used to
examine the differences between groups.
Survival times for the two groups were also
compared using Cox proportional hazard
model. Multivariable method was used to allow
for differences in profile between the EG and
NG-DES groups. The following covariates were
considered: age, gender, diabetes mellitus,
hypertension, dyslipidemia, current smoking,
family history of coronary artery disease, previ-
ous MI, previous PCI, previous CABG, left ven-
tricular ejection fraction, glomerular filtration
rate (GFR) \30 ml/min, lesion type B2/C,
chronic total occlusions (CTO), multivessel
coronary disease, culprit lesion in the left main
(LMT) coronary artery and acute coronary syn-
drome (ACS). Covariates to be used in multi-
variable models were found in two stages, first
omitting variables with p value[0.1 in a model
just including the variable and group and then
carrying out a backward elimination procedure
with the remaining variables. In the backward
elimination procedure, non-significant vari-
ables were dropped one-by-one until only sig-
nificant variables remained in the model. All
reported p values were two-sided, and p values
\0.05 were considered statistically significant.
Statistical analysis was performed using Stata SE
14 (StataCorp LP, College Station, TX, USA) and
SAS version 9.4 (SAS Institute Software GmbH,
Vienna, Austria) statistical software.
RESULTS
During the study period, a total of 588 patients
underwent RA. Of these, 107 patients were
excluded from the study (52 patients treated
with BMS, 14 treated with combination of DES
and BMS, 12 treated with a combination of early
and new generations DES, five treated with BVS,
nine patients treated with experimental stents
within clinical trials or in a randomized study
where the operator was blinded to the type of
stent, and 15 patients with no stent implanta-
tion). Thus, 481 patients received only early or
only new-generation DES and constitute the
population of the current analysis. Of these, 268
(55.7%) were treated with EG-DES for 288
lesions (61 lesions with Cypher stent, 225 with
Taxus stent and both stent types in two lesions),
and 213 patients (44.3%) received NG-DES for
225 lesions (82 lesions with Xience stent, 59
with Promus stent, 72 with Orsiro and 12 lesions
were treated with a mixture of two NG-DES).
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Patient, Angiographic, and Procedural
Characteristics
Baseline clinical characteristics are reported in
Table 1. The mean age of the study population
was 72 ± 8 years and 353 patients (73.3%) were
males. Left ventricular ejection fraction (LV-EF)
was reduced in 29.2% of the patients. 24.7% of
RA was performed in patients presenting with
an acute coronary syndrome. EG-DES and
NG-DES patients were not significantly different
in the latter aspects. However, significantly
more patients in the EG-DES group had dys-
lipidemia (75.6% vs. 61.1%; p = 0.001), a family
history of premature coronary artery disease
(26.3% vs. 16.8%; p = 0.014) or MI (25.7% vs.
16.4%; p = 0.014), while in the NG-DES group
diabetes mellitus (31.9% vs. 40.9%; p = 0.04)
and multivessel coronary artery disease (82.5%
vs. 90.9%; p = 0.008) were more frequent.
Lesion characteristics and procedural details
are presented in Table 2. In general, the NG-DES
cohort had more complex lesions and more
complex procedures. In the NG-DES group 39
lesions were located in LMT whereas only 22
lesions involving the LMT were treated in the
EG-DES group (p\0.001). Furthermore, the
number of CTO in the NG-DES group was sig-
nificantly higher (3.5 vs. 8.5%; p = 0.016).
Patients who received NG-DES after RA had a
significantly higher rate of multiple stent
implantation (48.6 vs. 63.1%; p = 0.001) as well
as a longer median stent length (30.5, IQR
20–40 mm vs. 38, IQR 22–53 mm; p\0.001).
High angiographic success rates were achieved
in both groups (97.2 vs. 96.9%; p = 0.82).
Iatrogenic coronary perforation occurred in
only one case in the EG-DES but was reported in
seven patients in the NG-DES group (p = 0.012).
Other procedural complications were rare and
similar between the groups.
In-Hospital Outcome
In-hospital death occurred in 1.1 and 1.4% of
the patients in the EG-DES and NG-DES group,
respectively (p = 0.77). All deaths were due to
cardiovascular cause. Thirty-two patients
developed MI during hospitalization (6.6%), of
which three were Q-wave MI. Overall, the inci-
dence of peri-procedural MI was higher in the
group of patients who received NG-DES after RA
(8.9%) compared to the patients who were
treated with EG-DES (4.8%) even though sta-
tistical significance was not reached (p = 0.07).
In-hospital TVR (0.8% vs. 0.5%, p = 0.57) and
TLR (0.4% vs. 0.5%, p = 0.69) were not signifi-
cantly different between EG-DES and NG-DES
groups.
Two-Year Outcome
Long-term clinical follow-up was available in
457 patients with a median follow-up period of
32 months (IQR 23–60) in the EG-DES group
and 17 months in the NG-DES population (IQR
12–31) (Fig. 1). There was no significant dif-
ference between the groups for the estimated
rate of MI (4.9% vs. 4.1%, log rank p = 0.89)
and TVR (17.6% vs. 12.9%, log-rank p = 0.19)
at 2 years, with a trend towards a lower rate of
TLR (12.7% vs. 7.9%, log-rank p = 0.13) in the
NG-DES group. All-cause mortality was
numerically higher in the EG-DES group
(13.5% vs. 8.2%, log-rank p = 0.13) due to a
significantly higher incidence of death from
non-cardiovascular causes (8.2% vs. 1.5%, log
rank p = 0.05). Cardiovascular mortality was
not significantly different (5.8% vs. 6.8%,
log-rank p = 0.64). However, the Kaplan–Meier
estimated rate of MACE showed a significant
reduction in the EG-DES group (31.1% vs.
21.1%, log-rank p = 0.04) (Fig. 1). By multi-
variable analysis, the use of new-generation
DES was independently associated with a lower
incidence of all cause mortality (HR 0.49; 95%
CI 0.26–0.92; p = 0.03), and the superiority of
NG-DES for reducing MACE rate was confirmed
(HR 0.65; 95% CI 0.42–0.98; p = 0.04) (Fig. 2).
Cardiovascular mortality was not statistically
different between the two groups (HR 0.82;
95% CI 0.37–1.85) as well as the incidence of
definite and probable stent thrombosis (0.9%
in the EG-DES and 2.4% in NG-DES group,
log-rank p = 0.13, adjusted HR 3.33; 95% CI
0.64–17.28; p = 0.15).
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DISCUSSION
The presence of calcified coronary arteries is
associated with worse outcomes in the general
population and in patients undergoing
revascularization [16, 17]. In the field of surgical
revascularization, severely calcified lesions have
been associated with atheroembolic complica-
tions and incomplete revascularization after
coronary artery bypass graft surgery (CABG). In
Table 1 Baseline clinical characteristics of the study population (481 patients)
Overall (n 5 481
patients)
EG-DES (n5 268
patients)
NG-DES (n5 213
patients)
p value*
Age (years) 72 ± 8 71 ± 8 72 ± 9 0.14
Male sex 353 (73.4%) 195 (72.8%) 158 (74.2%) 0.73
Cardiovascular risk factors
Diabetes mellitus 170 (35.9%) 85 (31.9%) 85 (40.9%) 0.04
Hypertension 434 (91.6%) 239 (89.9%) 195 (93.7%) 0.13
Dyslipidemia 328 (69.2%) 201 (75.6%) 127 (61.1%) 0.001
Current smoking 166 (35%) 96 (36.1%) 70 (33.7%) 0.58
Family history of premature
CAD
105 (22.2%) 70 (26.3%) 35 (16.8%) 0.01
Height (cm) 172 ± 9 172 ± 9 171 ± 9 0.48
Weight (kg) 82 ± 16 83 ± 16 81 ± 17 0.65
Body mass index (kg/m2) 27.8 ± 4.8 27.8 ± 4.8 27.8 ± 4.9 0.83
LV ejection fraction 52 ± 14 53 ± 11 51 ± 14 0.19
LV ejection fraction\50% 138 (29.2%) 71 (27%) 67 (32.1%) 0.23
Clinical history
Multivessel disease 412 (86.2%) 221 (82.5%) 191 (90.9%) 0.008
Prior myocardial infarction 104 (21.6%) 69 (25.7%) 35 (16.4%) 0.01
Prior PCI 183 (38%) 92 (34.3%) 91 (42.33%) 0.06
Prior CABG 86 (17.9%) 42 (15.7%) 44 (20.7) 0.16
Renal dialysis 9 (1.9%) 2 (0.75%) 7 (3.3%) 0.08
Severe CKD (GFR\30) 34 (7.7%) 17 (6.5%) 17 (8%) 0.49
Clinical presentation 0.22
Stable CAD 362 (75.3%) 196 (73.1) 166 (77.9%)
ACS 119 (24.7%) 72 (26.9%) 47 (22.1%)
Data presented as mean ± standard deviation or number and percentage
ACS acute coronary syndrome, CABG coronary artery bypass grafting, CKD chronic kidney disease, EG-DES early gen-
eration drug-eluting stents, CAD coronary artery disease, GFR glomerular ﬁltration rate, LV left ventricular, NG-DES
new-generation drug-eluting stents, PCI percutaneous coronary intervention, RA rotational atherectomy
*p value for comparison EG-DES vs. NG-DES
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Table 2 Angiographic and procedural characteristics (513 lesions)
Overall (n5 513
lesions)
EG-DES (n5 288
lesions)
NG-DES (n5 225
lesions)
p value*
Target vessel \0.001
Left main 61 (11.9%) 22 (7.6%) 39 (17.3)
Left anterior descending 259 (50.5%) 171 (59.4%) 88 (39.1%)
Right coronary artery 66 (12.9%) 36 (12.5%) 30 (13.3%)
Left circumﬂex 127 (24.8%) 59 (20.5%) 68 (30.2)
Chronic total occlusion 29 (5.6%) 10 (3.5%) 19 (8.5%) 0.01
Bifurcation lesion 201 (39.2%) 109 (37.8%) 92 (40.9%) 0.48
Ostial lesion 117 (22.8%) 61 (21.2%) 56 (24.9%) 0.32
ACC/AHA type B2/C 437 (85.2%) 226 (78.5%) 211 (93.8%) \0.001
Elective RA 312 (60.8%) 207 (71.9%) 105 (46.7%) \0.001
Predilatation 456 (88.9%) 250 (86.8%) 206 (91.6%) 0.07
Burr sizes 0.07
1.25 135 (26.3%) 63 (21.9%) 72 (32%)
1.5 234 (45.6%) 138 (47.9%) 96 (42.7%)
1.75 111 (21.6%) 66 (22.9%) 45 (20%)
2 33 (6.4%) 21 (7.3%) 12 (5.3%)
More than 1 burr 76 (14.8%) 42 (14.6%) 35 (15.1%) 0.21
Multiple stenting 282 (55%) 140 (48.6%) 142 (63.1%) 0.001
Number of implanted stents 1.8 ± 0.9 1.7 ± 0.8 2 ± 0.9 \0.001
Stent diameter 2.93 ± 0.42 2.93 ± 0.37 2.93 ± 0.48 0.84
Total stent length per lesion 32 (22-48) 30.5 (20-40) 38 (22-53) \0.001
Burr/artery ratio 0.52 ± 0.08 0.53 ± 0.08 0.52 ± 0.09 0.12
Postdilatation 312 (61.2%) 163 (57.2%) 149 (66.2%) 0.04
Postdilatation balloon size
(mm)
3.34 ± 0.52 3.29 ± 0.47 3.40 ± 0.58 0.06
Slow ﬂow 15 (2.9%) 5 (1.7%) 10 (4.4%) 0.07
Dissection 35 (6.8%) 15 (5.2%) 20 (8.9%) 0.10
Perforation 9 (1.75%) 1 (0.3%) 8 (3.6%) 0.01
Pericardial effusion 11 (2.1%) 4 (1.4%) 7 (3.1%) 0.22
Procedural duration (min) 85 ± 43 78 ± 44 95 ± 41 \0.001
Fluoroscopy time (min) 22 (15–33) 21 (14–31) 25 (16–36) 0.003
Contrast amount (ml) 226 ± 116 219 ± 114 234 ± 119 0.15
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percutaneous coronary treatment, calcified
lesions increase the likelihood of procedural
failure and complications after balloon angio-
plasty [18]. Lesion preparation by improving
vessel compliance with cutting and scoring
balloon has been demonstrated to enhance DES
expansion [19]. Rotational atherctomy exerts a
differential ablative effect on hard and soft
surfaces, transforming the calcified superficial
part of the plaque into small particles. Rota-
tional atherectomy became the most popular
atheroablative method in contemporary percu-
taneous coronary revascularization since the
introduction of drug-eluting-stents, which have
considerably reduced the rate of restenosis [1].
In this retrospective analysis, we analyzed
the performance of NG-DES compared to
EG-DES after RA. The main finding of this study
is that NG-DES resulted in lower rates of mor-
tality and major adverse cardiac events at
2 years in an all-comers population of patients
treated with RA, despite the fact that they were
used in more complex patients and lesions.
Naturally, most patients receiving EG-DES
were included in the early period of the registry,
while patients with NG-DES were treated more
recently. The different time periods might point
towards changing indications for RA and
explains at least in part the difference observed
in lesion characteristics between the groups.
Table 2 continued
Overall (n5 513
lesions)
EG-DES (n5 288
lesions)
NG-DES (n5 225
lesions)
p value*
Angiographic success 498 (97.1%) 280 (97.2%) 218 (96.9%) 0.82
Data presented as mean ± standard deviation, median and interquartile range or number and percentage
ACC/AHA American College of Cardiology, American Heart Association, EG-DES early generation drug-eluting stents,
NG-DES new generation drug-eluting stents, RA rotational atherectomy
*p value for comparison EG-DES vs. NG-DES
Fig. 1 Kaplan–Meier curve for the cumulative incidence
of MACE (a), death (b), MI (c), TVR (d), and TLR (e) in
patients treated with EG-DES vs. NG-DES after rotational
atherectomy. EG-DES early generation drug-eluting stents,
NG-DES new-generation drug-eluting stents, MACE
major adverse cardiac events, MI myocardial infarction,
TLR target lesion revascularization, TVR target vessel
revascularization
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After the ROTAXUS study [10] and the publi-
cation of the ESC/EACTS guidelines on
myocardial revascularization [20] we confined
the use of RA to bailout situations or very
complex lesions, which is mirrored in the
NG-DES group. Consequently, longer stents and
procedures as well as more peri-procedural
complications such as no reflow and coronary
perforations were observed in the NG-DES
group. Nevertheless, the technical aspects of RA
such as burr size, burr to artery ratio and the use
of multiple burrs were constant throughout the
study periods and the selection bias did not
result in lower angiographic success rates or
significantly worse in-hospital outcomes.
Calcified coronary lesions are more likely to
have suboptimal results after PCI due to their
resistant burden which may lead to incomplete
stent expansion, damage to the polymer/drug
coating during stent advancement and impair-
ment of local drug delivery through the calcium
[21]. Previous studies reported poor outcomes
after PCI of calcified lesions. Ge´ne´reux et al. in a
pooled analysis form the HORIZONS-AMI
(Harmonizing Outcomes with Revascularization
and Stents in Acute Myocardial Infarction) and
ACUITY (Acute Catheterization and Urgent
Intervention Triage Strategy) trials reported a
MACE rate of 16.1% at 1 year in patients with
moderate/severe coronary calcified lesions and
demonstrated that lesion calcification was
strongly predictive of stent thrombosis and
ischemic TLR [22]. In the ROTAXUS random-
ized trial, the systematic use of RA before
paclitaxel-eluting TAXUS stent implantation
did not result in an improvement of 9-months
and 2-year clinical outcomes with MACE rates
up to 29.4% after 2 years [10, 11]. RA-related
thermal injury and platelet activation may
result in greater neointimal hyperplasia and
higher late lumen loss after PCI, which coun-
terbalances the higher acute luminal gain
obtained during the index procedure [10, 21]. In
our analysis, 78% of patients in the EG-DES
group received the TAXUS stent and MACE rate
at 2 years was similar to the rate reported in the
ROTAXUS study.
It should be underlined that the superiority
of NG-DES in terms of reducing MACE in the
present study was mainly driven by a reduction
in the rate of mortality, while the reduction in
the TVR rate was less pronounced. As the tech-
nique of RA and the adjunctive therapies did
not change between either of the study groups,
an inherent mortality advantage might come
with the implantation of NG-DES. Accordingly,
by statistical risk adjustment models, the use of
new-generation DES was independently associ-
ated with significant lower mortality.
Similar results were reported from the SCAAR
registry, where the mortality reduction by
NG-DES was at least as strong as the anti-
restenotic effects compared to BMS as well as
EG-DES [23]. Potential mechanisms of NG-DES
superiority come from histo-pathological studies
in autopsy cases. NG-DES demonstrate greater
endothelial strut coverage with less inflamma-
tion, less fibrin deposition, and less late and very
late stent thrombosis compared to EG-DES [24].
Differences in mortality in PCI trials com-
paring both device generations are usually
demonstrated after long follow-up periods. In
the SPIRIT (Clinical Evaluation of the Xience V
Everolimus Eluting Coronary Stent System in
the Treatment of Patients with De Novo Cor-
onary Artery Lesions) trials the clinical superi-
ority of everolimus-eluting stents over
paclitaxel-eluting stents with respect to all-
cause mortality was not documented before the
Fig. 2 Adjusted interaction between the type of implanted
stent and outcomes at 2 years. Variables are adjusted using
multivariable Cox regression analysis and reported as
hazard ratio with 95% conﬁdence interval. EG-DES early
generation drug-eluting stents, HR hazard ratio, NG-DES
new-generation drug-eluting stents, LL lower limit,MACE
major adverse cardiac events, MI myocardial infarction,
TLR target lesion revascularization, TVR target vessel
revascularization, UL upper limit
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final 3-year clinical results [25]. In the present
study, the long duration of follow-up probably
made the survival benefit with NG-DES appar-
ent. Nonetheless, even after 2-year follow-up,
everolimus eluting stents were not superior to
paclitaxel eluting stents in diabetics as shown in
a meta-analysis of the SPIRIT and COMPARE
trials, which is remarkable since 40% of our
NG-DES patients suffered from diabetes [26].
In the RA field, Iannaccone et al. recently
performed a retrospective analysis of outcome
of RA in very long coronary lesions from the
ROTATE registry. In this study a multivariate
analysis as well as a sensitivity analysis showed
that the use of NG-DES was protective against
MACE [27].
Study Limitations
Some limitations of the current study need to be
mentioned. First, the analysis was conducted in
a single-center, retrospective and non-random-
ized study and therefore has all the limitations
of an observational study. Second, both study
groups were not uniform in the components of
the stents, but represent common patterns of
both DES generations. Third, the groups were
treated at different time periods and thus oper-
ator experience might have influenced the
results. Fourth, many differences were observed
between the groups in their clinical and angio-
graphic baseline characteristics. Furthermore,
some important parameters that could influ-
ence outcome such as the use of intravascular
imaging and duration of dual anti-platelet
therapy were not collected and analyzed in the
registry. Additionally, the clinical implication
of this study is limited with the fact that cur-
rently almost all patients are treated with
NG-DES. Finally, the difference observed in all
cause morality could be the result of a degree of
unmeasured confounding in this study.
Although meticulous statistical methods have
been used to adjust for baseline differences,
unmeasured confounders can never be exclu-
ded. Nevertheless, the analyzed data is from one
of the largest cohort of patients treated with RA
and a high rate of long-term clinical follow-up
was achieved.
CONCLUSIONS
Despite the treatment of more complex lesions
with new-generation as compared to early gener-
ation DES, use of NG-DES was associated with
lower rates of death and major adverse cardiac
events at 2 years in a population of patients with
severely calcified coronary lesions treatedwithRA.
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